ATE354362T1 - Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff - Google Patents

Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff

Info

Publication number
ATE354362T1
ATE354362T1 AT03770970T AT03770970T ATE354362T1 AT E354362 T1 ATE354362 T1 AT E354362T1 AT 03770970 T AT03770970 T AT 03770970T AT 03770970 T AT03770970 T AT 03770970T AT E354362 T1 ATE354362 T1 AT E354362T1
Authority
AT
Austria
Prior art keywords
amorphic
pharmaceutical composition
active ingredient
composition containing
stabilized pharmaceutical
Prior art date
Application number
AT03770970T
Other languages
English (en)
Inventor
Andrej Bastarda
Mateja Salobir
Rok Grahek
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE354362(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of ATE354362T1 publication Critical patent/ATE354362T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
AT03770970T 2002-10-11 2003-10-10 Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff ATE354362T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Publications (1)

Publication Number Publication Date
ATE354362T1 true ATE354362T1 (de) 2007-03-15

Family

ID=32091984

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03770970T ATE354362T1 (de) 2002-10-11 2003-10-10 Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
AT0010907U AT10424U1 (de) 2002-10-11 2007-02-20 Fertigarzneimittel, enthaltend ein in inertgas gelagertes, amorphes atorvastatin-ca

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0010907U AT10424U1 (de) 2002-10-11 2007-02-20 Fertigarzneimittel, enthaltend ein in inertgas gelagertes, amorphes atorvastatin-ca

Country Status (21)

Country Link
US (2) US20040077708A1 (de)
EP (1) EP1608362B1 (de)
CN (1) CN100372529C (de)
AR (1) AR041588A1 (de)
AT (2) ATE354362T1 (de)
AU (1) AU2003280361B2 (de)
CY (1) CY1106608T1 (de)
CZ (1) CZ17610U1 (de)
DE (2) DE20321455U1 (de)
DK (2) DK1608362T3 (de)
ES (1) ES2285205T3 (de)
FI (1) FI7617U1 (de)
ME (1) ME00514B (de)
PT (1) PT1608362E (de)
RS (1) RS51819B (de)
RU (1) RU2358727C2 (de)
SI (2) SI21302A (de)
SK (1) SK5233Y1 (de)
TW (1) TWI320709B (de)
UA (1) UA85544C2 (de)
WO (1) WO2004032920A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2003057593A1 (en) 2001-12-21 2003-07-17 Nektar Therapeutics Capsule package with moisture barrier
DE602004010817T2 (de) * 2003-08-05 2008-12-11 Zentiva, A.S. Verfahren zur stabilisierung von atorvastatin
CN1942439B (zh) 2004-03-17 2011-12-21 兰贝克赛实验室有限公司 无定形形式的阿托伐他汀钙的制备方法
CA2833770A1 (en) 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D Oxidative degradation products of atorvastatin calcium
EP1793815A4 (de) * 2004-09-30 2010-12-29 Reddys Lab Ltd Dr Amorphes atorvastatincalcium
EP1819319A1 (de) * 2004-12-02 2007-08-22 Warner-Lambert Company LLC Pharmazeutische zusammensetzungen von amorphem atorvastatin und herstellungsverfahren dafür
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (de) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (de) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Einheitsdosenverpackung
KR20120128599A (ko) 2009-12-25 2012-11-27 사와이세이야쿠 가부시키가이샤 아트로바스타틴 함유 피복 제제
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
EP3265078A1 (de) * 2015-02-03 2018-01-10 Kadmon Pharmaceuticals, LLC Stabile trientinformulierungen
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (de) 2015-12-21 2017-06-28 Hexal AG Pharmazeutische zusammensetzung mit atorvastatin oder einem salz davon

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (de) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
CA2201354A1 (en) * 1994-09-30 1996-04-11 Becton, Dickinson And Company Method for forming and packaging iontophoretic drug delivery patches and the like to increase stability and shelf-life
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
AU2000250960A1 (en) * 2000-06-09 2001-12-17 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Ausgabeeinheit für sauerstoff-empfindlichen Medikamenten

Also Published As

Publication number Publication date
SK5233Y1 (en) 2009-09-07
ME00514B (me) 2011-10-10
FIU20070036U0 (fi) 2007-01-26
SI1608362T1 (sl) 2007-12-31
US20090012150A1 (en) 2009-01-08
RU2358727C2 (ru) 2009-06-20
US20040077708A1 (en) 2004-04-22
WO2004032920A1 (en) 2004-04-22
AR041588A1 (es) 2005-05-26
FI7617U1 (fi) 2007-09-28
CY1106608T1 (el) 2012-01-25
UA85544C2 (ru) 2009-02-10
DK200700025U1 (da) 2007-06-08
TW200501947A (en) 2005-01-16
CN1703215A (zh) 2005-11-30
DK200700025U4 (da) 2008-03-14
EP1608362B1 (de) 2007-02-21
CN100372529C (zh) 2008-03-05
AT10424U1 (de) 2009-03-15
EP1608362A1 (de) 2005-12-28
DE20321455U1 (de) 2007-05-24
CZ17610U1 (cs) 2007-06-18
ES2285205T3 (es) 2007-11-16
AU2003280361B2 (en) 2009-02-26
PT1608362E (pt) 2007-05-31
DE60312049D1 (de) 2007-04-05
AU2003280361A1 (en) 2004-05-04
SI21302A (sl) 2004-04-30
RU2005114485A (ru) 2006-01-27
SK50062007U1 (en) 2009-03-05
TWI320709B (en) 2010-02-21
RS51819B (sr) 2011-12-31
DK1608362T3 (da) 2007-05-14
DE60312049T2 (de) 2007-10-04
RS20050273A (en) 2007-06-04

Similar Documents

Publication Publication Date Title
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
ATE460169T1 (de) Pharmazeutische formulierung mit lanthanum- verbindungen
PT1501534E (pt) Formulacoes farmaceuticas
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DE60307677D1 (de) Dispergierbare pharmazeutische zusammensetzungen
ATE317260T1 (de) Pharmazeutische formulierungen mit platinderivaten
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
DE60142197D1 (de) Pharmazeutische Zusammensetzung
IS7571A (is) Ný lífeðlisfræðilega virk efni
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
DE60210139D1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
NO20054214D0 (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
ATE327759T1 (de) Pharmazeutische zusammensetzung mit verlungerter freisetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ATE332690T1 (de) Perindopril enthaltende pharmazeutische zusammensetzung mit oraler dispersion
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ITRM20020119A0 (it) Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
DE60217369D1 (de) Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608362

Country of ref document: EP